Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 15/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23195806 | 0.89 | MAPK8 (0.61) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL23195805 | 0.87 | MAPK8 (0.58) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14667081 | 0.85 | MAPK8 (0.78) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL24591388 | 0.81 | MAPK8 (0.58) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14659020 | 0.80 | MAPK8 (0.96) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL22100989 | 0.80 | MAPK8 (1.00) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL22447049 | 0.80 | MAPK8 (1.00) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14658544 | 0.80 | MAPK8 (1.00) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14658007 | 0.79 | MAPK8 (0.69) | MAPK8MAPK9ADORA3MAPK10SYK | |
| SCHEMBL14658005 | 0.79 | MAPK8 (0.69) | MAPK8MAPK9ADORA3MAPK10SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104283-A1 | JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2023-04-06 | — | — | US | disclosed |
| EP-4023642-A1 | JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021063207-A1 | JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104283-A1 | JNK INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | MAPK1, MAP3K21, MAPK14 | MAPK8 38/4885MAPK9 35/4885ADORA3 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.